Suvoda Launches New Drug Optimization as Part of Latest Interactive Response Technology Release
Added feature offers cost savings and the ability to reduce carbon footprint, company says.
Suvoda LLC, a clinical trial technology company, announced a new advanced drug optimization feature as part of its latest interactive response technology (IRT) release. According to the company, this feature offers sponsors of clinical drug trials improved drug supply management, delivering cost savings, and helping companies to reduce their carbon footprint. In the past, supply strategies depended on static quantities of initial drug shipments and buffers, often leading to excessive orders to ensure enough medication is available during a trial.
"Suvoda's new enhancement is an example of how we listen to the needs of our customers and deliver tools that help our sponsors and partners," said Lisa Li, director of IRT product management, Suvoda. "We heard from drug supply managers that they were concerned about the impact of drug oversupply across the entire supply chain, including raw materials, manufacturing, storage, shipping, and packing materials. Helping study managers fine-tune supply can maximize trial resources and increase efficiencies."
Reference: Suvoda Introduces Advanced Drug Optimization for IRT to Improve Accuracy of Clinical Trial Drug Supply Management. PR Newswire. October 12, 2023. Accessed October 13, 2023. https://www.prnewswire.com/news-releases/suvoda-introduces-advanced-drug-optimization-for-irt-to-improve-accuracy-of-clinical-trial-drug-supply-management-301951747.html
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
